Home › NDC Lookup › Ingredients › Cefepime Hydrochloride › 25021-0121-20
💉image loading
(from DailyMed)

cefepime 1 g/20mL Injection, Powder, For Solution, 10 vials — NDC 25021-121-20 (Billing 25021-0121-20)

by Sagent Pharmaceuticals · 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

This is a package of 10 vials of cefepime 1 g/20mL Injection, Powder, For Solution from Sagent Pharmaceuticals, marketed since May 2008 and currently FDA-listed; retail pharmacies pay about $3.73 per vial (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 25021-0121-20
🏷️ FDA NDC (as labeled) 25021-121-20 billing pads the product segment with a zero
This package
Contains10 vials Cost per ea$3.73 NADAC Per package$37.31 / 10 injection Pack sizes2 compare ↓
Also priced by: Medicaid pays $14.25/unit · Part D plans $5.37/unit — full pricing hub ↓
Main listing for product 25021-121 · Also comes in: 10 vials 25021-121-66
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Sep 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 25021-121-20 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
25021 labeler · 121 product · 20 package
Package marketed since
May 1, 2008
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
10 EA per package
Barcode (UPC-A, from the NDC)
3 2502112120 7
Medicaid fills, this package
2,346 prescriptions in the last four reported quarters
FDA record last changed
Sep 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 25021-121-20
Product NDC 25021-121
11-digit billing NDC 25021012120
NCPDP billing unit EA — each (per item)
Application # ANDA065441
SPL Set ID f5f4ce71-3a77-4670-805b-4c346a0f9bea
Established class (EPC) Cephalosporin Antibacterial
Chemical class Cephalosporins
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2008-05-01
Route INTRAMUSCULAR, INTRAVENOUS
Dosage form INJECTION, POWDER, FOR SOLUTION
Substance CEFEPIME HYDROCHLORIDE
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 024094
GCN 49122
HICL code 010132
Ingredient (HICL) Cefepime Hcl
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1Z
Therapeutic class — specific (HIC3) Cephalosporin Antibiotics - 4Th Generation
AHFS code 08:12.06.16
AHFS class 4Th Generation Cephalosporin Antibiotics
FDB label name CEFEPIME HCL 1 GM VIAL
FDB brand name Cefepime Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 024094
  • GCN: 49122
  • HICL (First Databank): 010132
  • AHFS class code: 08:12.06.16
Why two NDCs? The FDA registers this code as 25021-121-20 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 25021-0121-20. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name CEFEPIME HCL 1 GM VIAL Ingredient Cefepime Hcl
📗 Our plain-language guide HelloPharmacist
  • Cefepime is only available as an injection — there's no pill form. It's designed for serious bacterial infections that need a strong antibiotic delivered directly into your bloodst...
  • Why am I getting cefepime through an IV instead of just taking an antibiotic pill?
  • The most common things people notice are redness, pain, or swelling near the injection or IV site, along with rash, nausea, diarrhea, or headache — these are usually manageable. Wh...
  • What side effects should I actually expect, and which ones mean I should speak up right away?
📖 Read our full Cefepime Injection guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
7
Nutrient depletion considerations

Cefepime may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Cefepime nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $3.731 $37.31 / 10 injection
Medicaid paysCMS SDUD · 12 mo $14.25 $142.51 / 10 injection
Medicare drug plans payPart D · Q2 2026 $5.37 $53.69 / 10 injection
Medicare Part B allowsASP · J0692 $1.296 / J0692 unit —
NADAC price history (per ea) — tap or hover for the price & month
Aug 2025 $3.731 $3.731
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)25021-121-20
11-digit billing NDC25021-0121-20
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ0692
DescriptorInjection, cefepime hydrochloride, 500 mg
Billing units / pkg20 units
How the units are derivedThis package is 1; the HCPCS unit is 500 MG, so one package = 20 billing units.
Medicare Part B spend (2026 (Q1))$30,324 · 4,085 claims · $7.42 per claim (all NDCs under J0692)
Crosswalk sourceCMS ASP NDC-HCPCS Crosswalk
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
25021-0121-66 25021-121-66 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL — — 2015-07-01 — Discontinued by firm
25021-0121-20 You're viewing this Main listing 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL $3.73 / ea $37.31 2008-05-01 — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 10 vials — 10 vial in 1 carton / 1 injection, powder, for solution in 1 vial.
How does this package differ from NDC 25021-0121-66?
Both are cefepime 1 g/20mL Injection, Powder, For Solution — the drug itself is identical. This page's package is the 10 vials one, while NDC 25021-0121-66 is the 10 vials package.
What NDC number is used to bill for this package of cefepime 1 g/20mL Injection, Powder, For Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Cefepime 1 g 00409-9566-10 Hospira, 10 vials $3.731 AP Availability likely —
cefepime 1 g/20mLthis 25021-0121-20 Sagent 10 vials $3.731 AP Availability likely —
Cefepime 1 g 44567-0130-10 WG 10 vials $3.731 AP Availability likely —
Cefepime 1 g 44567-0240-10 WG 10 vials $3.731 AP Availability likely —
Cefepime 1 g 60505-6144-04 Apotex 10 vials $3.731 AP Availability likely —
Cefepime 1 g 60505-6245-04 Apotex 10 vials $3.731 AP Availability likely —
Cefepime 1 g 63323-0326-20 Fresenius 10 vials $3.731 AP Availability likely —
Cefepime Hydrochloride 1 g 00143-9382-10 Hikma 10 vials — AP FDA listed —
Cefepime Hydrochloride 1 g 00143-9477-10 Hikma 10 vials — AP FDA listed —
Cefepime Hydrochloride And Dextrose 1 g/50mL 00264-3193-11 B. 50 ml — — FDA listed —
Cefepime 1 g/50mL 00338-1301-41 Baxter 50 ml — — FDA listed —
Cefepime 1 g 60505-6146-00 Apotex 1 vial — AP FDA listed —
Cefepime 1 g 67184-1003-01 Qilu 10 vials — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2008
On the market since
May 2008
📍
2026
Currently FDA-listed
18 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Cefepime Injection inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSagent Pharmaceuticals
Application holderACS DOBFAR SPA
FDA applicationANDA065441 (ANDA)
Labeler code25021
First marketedMay 2008
Product typeHuman Prescription Drug
Portfolio209 products on file

More NDCs from Sagent Pharmaceuticals labeler code 25021

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.3K
Units reimbursed last 4 qtrs
9.6K
Gross reimbursed last 4 qtrs
$137.5K
Avg / prescription
$58.60
Avg / unit
$14.2508
Latest quarter Q1 2026
381Rx
Medicaid pays / ea
$14.2508
gross reimbursed
vs
NADAC / ea
$3.7308
acquisition cost
=
Spread
+$10.5200
+282% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
22% FFS 78% MCO
Fee-for-service · 511 Rx Managed care · 1,835 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 22 units · 0.3 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 63 units · 0.6 per 100k residents MI New York: 857 units · 4.4 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 65 units · 1.5 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 89 units · 0.7 per 100k residents IL Indiana: no data reported IN Ohio: 945 units · 8.0 per 100k residents OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: 74 units · 1.1 per 100k residents MA California: 802 units · 2.1 per 100k residents CA Utah: no data reported UT Colorado: 18 units · 0.3 per 100k residents CO Nebraska: no data reported NE Missouri: 238 units · 3.8 per 100k residents MO Kentucky: 12 units · 0.3 per 100k residents KY West Virginia: 37 units · 2.1 per 100k residents WV Virginia: no data reported VA Maryland: 22 units · 0.4 per 100k residents MD Connecticut: no data reported CT Rhode Island: 600 units · 54.8 per 100k residents RI Arizona: 631 units · 8.5 per 100k residents AZ New Mexico: 248 units · 11.7 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 2,918 units · 40.9 per 100k residents TN North Carolina: 393 units · 3.6 per 100k residents NC South Carolina: 64 units · 1.2 per 100k residents SC Delaware: 32 units · 3.1 per 100k residents DE Oklahoma: 31 units · 0.8 per 100k residents OK Louisiana: 168 units · 3.7 per 100k residents LA Mississippi: no data reported MS Alabama: 108 units · 2.1 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: 278 units · 19.4 per 100k residents HI Texas: 452 units · 1.5 per 100k residents TX Florida: 481 units · 2.1 per 100k residents FL
Units reimbursed · per 100k residents
0.354.8
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 54.8 /100k
2 Tennessee 40.9 /100k
3 Hawaii 19.4 /100k
4 New Mexico 11.7 /100k
5 Arizona 8.5 /100k
6 Ohio 8.0 /100k
7 New York 4.4 /100k
8 Missouri 3.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
10 vials this page25021-0121-20 2,346 Rx · $137,478
10 vials25021-0121-66 No Medicaid data
Drug total (last 4 qtrs): 2,346 Rx · 9,647 units · $137,478 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Cefepime — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Cefepime. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$154.2K
Claims incl. refills
565
Beneficiaries
208
Spend / beneficiary
$741.33
Spend / claim
$272.91
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Cefepime (this brand).

Top reported reactions

Acute Kidney Injury1,267
Pyrexia1,085
Febrile Neutropenia877
Pneumonia807
Sepsis614
Hypotension592
Encephalopathy557

Age at onset

Neonate58
Infant59
Child132
Adolescent82
Adult1,361
Elderly1,024

Reporter sex

15,974 reports
Male · 56%
Female · 44%
Unknown · 0%

Serious outcomes

Hospitalization9,414
Death3,525
Life-threatening2,515
Disabling221
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,361 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 25021-0119-20 · Sagent 25021-0122-67 · Sagent →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.